

Targretin® (bexarotene) – First-time generic

- On May 24, 2022, Amneal launched an <u>AB-rated</u> generic version of Bausch Health's <u>Targretin</u> (bexarotene) topical gel.
 - Amneal was awarded 180-days of Competitive Generic Therapy exclusivity.
- Targretin gel is approved for the topical treatment of cutaneous lesions in patients with cutaneous T-cell lymphoma (CTCL) (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
- Bexarotene is also available as a generic <u>oral capsule</u> for the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least one prior systemic therapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.